Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Evolus and keeping the price target at $20.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Douglas Tsao has given his Buy rating due to a combination of factors that highlight Evolus’s resilience and strategic positioning in a challenging market. Despite a softer second quarter and adjusted expectations, the company showed sequential improvement, which is promising given the tough market conditions. The management’s reaffirmation of its net revenue guidance for 2025, expecting between $295 million and $305 million, underscores confidence in the performance of Jeuveau and the successful launch of Evolysse.
Additionally, Evolus reported a total revenue of $69 million, surpassing both the analyst’s estimate and consensus, with Jeuveau’s global net revenue marking an increase compared to the previous quarter. This growth, in contrast to the decline in Botox cosmetic sales by a competitor, reflects Evolus’s effective market strategy and customer engagement through its loyalty platform and marketing initiatives. The introduction of its own “portfolio” bundle and the upcoming launch of the Sculpt dermal filler further strengthen its competitive position. While cautious about macroeconomic challenges and tariffs, the company’s projected profitability and strategic initiatives support the Buy rating.
In another report released today, Mizuho Securities also reiterated a Buy rating on the stock with a $20.00 price target.